Actinium Pharmaceuticals, Inc. — Director's Dealing 2018

Jan 9, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Actinium Pharmaceuticals, Inc. (ATNM)
CIK: 0001388320
Period of Report: 2018-01-08

Reporting Person: Ludwig Dale L. (Chief Scientific Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Options to purchase common stock	$0.72	2028-01-08	Common Stock (200000)		Direct

Footnotes

F1: Options granted on January 8, 2018 to purchase an aggregate of 200,000 shares of common stock. A total of 28% of the options will vest one year from the grant date, and the remaining 75% shall vest in equal increments of 2% per month of the initial option grant over the following three year period.